We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EKF Ekf Diagnostics Holdings Plc

0.00 (0.0%)
28 Nov 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 28.00 27.50 28.50 28.50 28.50 28.50 291,797 16:35:05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -12.84 129.66M

Ekf Diagnostics Share Discussion Threads

Showing 4001 to 4024 of 4775 messages
Chat Pages: Latest  167  166  165  164  163  162  161  160  159  158  157  156  Older
EKF is not a pure play on COVID-19 testing, but it seems like a bit of an overreaction in terms of the share price reaction, but time will of course tell!

To my mind this new variant situation highlights the importance of the fact that we will need to perform genomic surveillance of COVID-19 for a very, very long time, and indeed the necessity of having access to relevant samples 'at scale' to do undertake this. EKF of course provide two specimen collection options.

Given current concerns regarding the new variant, along with the fact that current SARS-CoV-2 PCR diagnostics continue to detect the new variant, it maybe that the attributes of PrimeStore MTM (and possibly ATM) that effectively inactivate RNA, mRNA and DNA pathogens (including SARS-Cov-2) for safer and faster collection, whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications e.g. sequencing, could 'further' become the preferred option due to factors such as safer handling and more flexible/available transport options.

Recall that, unlike standard devices for collecting and transporting biological samples, PrimeStore® MTM begins to inactivate pathogens, proteins and enzymes immediately upon insertion, allowing the sample to be tested right away or shipped at ambient temperature to a testing facility anywhere in the world. Ambient specimen shipping for testing and sequencing would arguably suit certain climates, especially those with limited cold chain shipping options, and especially a sample collection option which enables highly sensitive molecular testing without subjecting workers to live infectious agents.

I note the following WHO release, which states

As such, countries are asked to do the following:

> enhance surveillance and sequencing efforts to better understand circulating SARS-CoV-2 variants.

> submit complete genome sequences and associated metadata to a publicly available database, such as GISAID.

>report initial cases/clusters associated with VOC infection to WHO through the IHR mechanism.

>where capacity exists and in coordination with the international community, perform field investigations and laboratory assessments to improve understanding of the potential impacts of the VOC on COVID-19 epidemiology, severity, effectiveness of public health and social measures, diagnostic methods, immune responses, antibody neutralization, or other relevant characteristics.

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
26 November 2021

Another aspect that also crossed my mind was how effective the current lateral flow tests (LFT) are at detecting the variant. And perhaps the fact that British nationals arriving from the red list countries who have been in these countries within the last ten days, must quarantine at home for ten days and take PCR tests on day two and day 8, even if they already have a lateral flow test, might imply that the LFT might miss the infection. In any regard, either way two at home PCR tests is a 'requirement'! Plus, I duly note that EKF recently confirmed a new contract for supply of PrimeStore MTM to testing labs based at major UK airports.

Elsewhere, I note that walk-in Covid-19 test centres are experiencing a surge in demand for PCR testing, and in reaction to the new variant, the Gujarat govt in India mandated RT-PCR testing at airports for travellers of 11 countries.

There is much more to EKF than COVID-19 testing, but it's worthy of note that the recent purchase of ADL Health positions EKF as a single provider able to encompass all products and services from ‘sample-to-result’, which of course has not yet been reflected in any previous update or results coverage.

On another note, the dividend payment is next week, which can be very useful for number of reasons/uses!

Like I said good luck - you will need it champ lol
I do ok thanks to you and your posts :-P you only have to shout BOO! and they sell.
Who exactly has profited from a sideways share? No need to reply - it's rhetorical pal. Good luck champ.
All i see is some profit taking IMHO.
Fundamentals to me seem intact.

EKF should benefit? Love the broken record argument again. Lol

we are in the midst of a pandemic with no end in sight and yet this stock hasn't gone anywhere in 13 months. ever question yourself why?

Translation - in all likelihood all pandemic related benefits to ekf have all been discounted by late Oct 2020. Been making the same point for over a year now. Did any of you ever read markets are forward looking machines and in the business of continuously discounting the future 12-18 months out?

Seriously folks, get a grip, think critically and grow up if you want to beat the market. more importantly, do away with wishful thinking. Hope is the most expensive word in the world of money - according to Sir John Templeton of course (am sure he knew a thing or two about the proverbial long term)

P.S. MG - care to update us on the latest performance numbers or shall we extrapolate to 2025 so that you're still happy? lol

Its the "NU" African virus that has hit the markets on a lot of shares rr,easyjet for example are hit hard for obvious reasons.
Ekf should benefit in a way as i said before covid has legs in it yet!.
Maybe a new vaccine may be needed since existing looses 40% effectiveness against this new variant.

Here we go chaps,73 printing.

Plenty on here have fallen in love with wan’s never changing thesis and refuse to see cold hard facts. Today we are hearing of a new covid related variant and yet ekf still tanks. Doesn’t this merit a proper discussion on this board? This is exactly what you should discuss - are you missing something in your broken record story? Literally.

Made exact same point on Nov 9 2020 but folks were up in arms.

LISTEN to what the market is telling you!

opens 3 liter bottle of white lightning
Time to uncork the bubbly then?
EKF in the BLUE within a big sea of RED this morning !
Fair to say it's toast now?
This breakout is def toast pal. What is less certain (with you being right there) is the (potential) next breakout (if it happens of course - if so I will make sure I climb on board but not feeling super confident we will see something along those lines soon).
Don't be to sure about this break out yet. The day is still early, we have a very crafty mm here.
Another failed breakout attempt. Another message (again) from Mr Market that everything folks talk about here is ALREADY in the price. Only catalyst that may help the share price rocket is a major, major positive surprise. That's what I hope someone tells us here not replay broken records about how markets have yet to catch-up with some anonymous board members here. Good luck chaps - listen to what the market is telling you.
I also viewed this as positive news. The final part of this particular jigsaw is to appoint the new COO. I also wonder if EKF are going to publish a trading update in the near future. They have been relatively quiet of late, compared to recent years.
CFO is leaving the company just told us. Not sure why but what one can be sure about is Peter Lynch was never a big fan of such high profile departures.
Indeed wan - an impressive appointment, and noteworthy that the new CFO is described as having "strong sector experience managing both organic and acquisitive growth".
The evolution of EKF continues with todays news!

Market wisdom has only just begun to acknowledge what the new EKF era might deliver in terms of reliable growth, but perhaps understandably, it's not yet acknowledging the exciting growth that will come from the further execution of their growth strategy. In this regard, I am very confident we can expect more news.

Suffice to say, I thus look forward to EKF climbing up the AIM 100 league table in due course!

Why the trolls lately tong? I prefer your flashes of genuine market wisdom, which I believe you have.
Morning wan - still waiting for the usual pal. Tic toc
Mg must agree with your assessment. Do you also believe second coming of the lord is also at hand? Lol
Due for tick up soon to mid 80,s since stable at current levels.
News from Medica 2021 (apologies wan if you've already posted this! I don't recall it....)

"EKF Diagnostics Showcases STAT-Site WB β-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
By LabMedica International staff writers
Posted on 15 Nov 2021

EKF Diagnostics (Cardiff, Wales, UK) showcased its recently launched STAT-Site WB β-ketone and glucose handheld analyzer at this year’s MEDICA, the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals....

....MEDICA 2021 became the venue for the first public viewing of the new STAT-Site WB β-ketone and glucose handheld analyzer in Europe since its global launch earlier this year. The STAT-Site WB analyzer from EKF is used for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples. The STAT-Site WB analyzer uses two different strips to provide results in just ten seconds for β-ketones and five seconds for glucose allowing for clear and comprehensive management of diabetes patients displaying early symptoms of ketosis to be quickly treated and then monitored on a regular basis.

EKF also demonstrated its globally successful PrimeStore MTM (Molecular Transport Medium) molecular transport media that gives the user a “snapshot” in time for that sample by preserving and stabilizing DNA and RNA. PrimeStore MTM was designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses, and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications.

In addition to PrimeStore MTM, EKF also demonstrated new product innovations relating to the future control of COVID-19, including the COVID-SeroKlir SARS-CoV-2 IgG antibody IVD kit. The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory without the need for proprietary equipment."

Chat Pages: Latest  167  166  165  164  163  162  161  160  159  158  157  156  Older

Your Recent History

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |